Form 4: C4 Therapeutics Director Bruce Downey Acquires Stock Options

Director Bruce Downey acquired 32,500 stock options in C4 Therapeutics, Inc. on June 20, 2024.

Summary

• On June 20, 2024, Bruce Downey, a director of C4 Therapeutics, Inc. (CCCC), acquired 32,500 stock options.
• The exercise price of these options is $4.05.
• The options vest fully on the earlier of June 20, 2025, or the next annual meeting of the Issuer's stockholders, contingent upon continued service on the Board.
• The options expire on June 19, 2034.
• Following the transaction, Downey directly owns 32,500 derivative securities.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard disclosure of stock option grants to a director. It doesn't inherently indicate positive or negative performance, but rather aligns interests.

Positives

• A director's acquisition of stock options can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The vesting of the options is contingent upon continued service as a member of the Board, suggesting an expectation of continued involvement.

Industry Context

This filing is a routine disclosure related to insider transactions, common in the biopharmaceutical industry where stock options are frequently used as part of executive compensation packages.

Comparison to Industry Standards

• Stock option grants are a common component of compensation packages for directors and executives in the biotechnology industry.
• Companies like Amgen, Gilead Sciences, and Biogen routinely grant stock options to their board members and key employees as incentives.
• The vesting schedule and exercise price are typical for such grants, aligning with industry norms for incentivizing long-term commitment and performance.

Stakeholder Impact

• The acquisition of stock options by a director could potentially boost investor confidence, as it aligns the director's interests with those of the shareholders.

Key Dates